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The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. My personal interest in gerontological research was spawned when I was engaged in basic research focusing on the agedependent decline of immune functions reflected by thymic involution. I was fascinated by the phenomenon of autoimmunity, the loss of immunological self-recognition leading to autoimmune diseases that begin early in life and become clinically manifest later [2]; my whole career as a gerontologist was motivated by the question of whether we can learn anything about the aging process by studying age-related diseases in animals and humans.
When we look at age-related diseases, it may be worthwhile to distinguish between those that are a primary manifestation of senescence, such as Werner's disease or Hutchinson-Gilford syndrome, and those which represent secondary phenomena, suffered as a consequence of reaching old
The
From the above-mentioned rectangular pattern of the human survival curve one can deduce that, based on an individual fixed genetic background, modification of environmental factors is presently the only tool to achieve 'healthy aging'.
The concept of pleiotropic antagonism is relevant when considering age-related diseases. It is based on the observation that genes that are beneficial early in life may play a detrimental role later on when they are expressed at sites other than their original position (pleiotropy). For instance, some genes allow for calcification of bones (osteocalcin and bone sialoprotein), making them stronger and improving fighting and fleeing capacity, but they acquire negative, antagonistic effects later in life if they are expressed elsewhere, leading, for example, to calcified atherosclerotic lesions. Therefore, the diseases of aging may be the price we pay for the vigor of youth.
It should also be reiterated that the natural rules underlying the development of age-related diseases are today skewed by the pace of change in human lifestyle (cultural evolution), which is far too fast for genetic adaptation to keep up with. Thus, we live under 21st century conditions with a pre-stone age genome. In the words of the evolutionary biologists Nesse and Williams, 'The price of not being eaten by a lion at the age of 30 may be a heart attack at 80' [4].
Anti-Aging and Science Kitsch
Often, gerontologists working in basic research at the single cell level, such as yeast, or with lower multicellular organisms, such as the worm C. elegans or the fruit fly Drosophila, are confronted with the risk of having their data overinterpreted, raising false hopes in lay people. Drum-beating by the scientists themselves in the media has tes, cancers, cardiovascular diseases, osteoporosis, arthrosis and dementia. It has, however, to be kept in mind that all these diseases start early in life -initially without clinical symptoms -and only become manifest in later years. Thus, diseases in older age are not the consequence of the body's failure, but rather the result of its long survival. However, in this context we should remind ourselves that the design of the human body is both astoundingly precise and surprisingly slipshod. Overall, it has been shaped by evolution to become an optimal compromise for its final destiny: reproduction. Importantly, natural selection is only effective during the reproductive period and individuals living into postreproductive age, as is the case for the majority of people in developed societies, are no longer subjected to selective pressure. The question of whether having grandparents increases the survival chances of an individual has still not been completely settled [3] . age because our cultural evolution by far outpaces biological evolution. However, I think such a distinction between 'pure' senescence and pathological age-associated processes is a rather academic issue, raising unnecessary barriers between basic and applied gerontological research that may impair the crucial and beneficial dialogue between various disciplines. In addition, we should not forget that gerontology in a broader sense encompasses many fields outside of biology, the aging society representing one of the most important socioeconomic problems facing not only the developed world, but increasingly also the less developed countries.
Age-Related Diseases: The Price for the Vigor of Youth
In 1900, the mean life expectancy in Central Europe and the USA was about 49 years. Since that time, life expectancy has increased more than in the 10,000 years before. This has been due to advances in medicine and hygiene, as well as improvements in socioeconomic conditions.
Although the mean life expectancy has increased, this has been associated with a rather constant value for maximally attainable age. When plotted on a graph, this leads to a 'rectangularization' of the human survival curve (Fig. 1, page 2 ). This observation is one of many indications that the aging process is governed by both genetic and environmental factors. Discussing this issue in depth is beyond the scope of this article. Suffice it to mention that different species exhibit different maximal lifespans that show a significant correlation with their capacity to repair DNA damage.
Increasing age is fraught with increasing morbidity. The list of diseases associated with aging is long and includes diabe- [1] . Except for these special cases, the somatic cells of all organisms undergo senescence, a process of age-dependent loss of function. Studying this phenomenon is both of theoretical and practical interest.
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During its long existen ce the University of Basel has hosted many infl uential and visiona ry thinke rs. Among those to walk the halls of the univer sity are Erasm us, the human ist and theolog ian, the famou s Bernoulli family of mathem aticians, Friedri ch Nietzsc he, the philoso pher, and Carl Gustav Jung, the psychi atrist. Today, the region of Basel is one of the world's leading life science centers , hostin g the headqu arters of pharm aceutic al giants Novart is and Roche alongs ide numer ous other drug compa nies and researc h institutions . In this, Basel has profi ted greatly from its strateg ic locatio n at the point where the border s of France and Germa ny meet Switze rland. It is import ant to remem ber that these outstan ding individ uals did not exist in ha Erasm us, the hum theolog ian, the famou s Bernoulli family of mathem aticians, Friedri ch Nietzsc he, the philoso pher, and Carl Gustav Jung, the psychi atrist. Today, the region of Basel is one of the world's leading life science centers , hostin g the headqu arters of pharm aceutic al giants Novart is and Roche alongs ide numer ous other drug compa nies and researc h institutions . In this, Basel has profi ted greatly from its strateg ic locatio n at the point where the border s of France and Germa ny meet Switze rland. Th e English composer Edward Elgar is reported to have said, 'there is music in the air,' and at the beginning of the 21st century this is indisputab le: on radio and television, at concerts and in the cinema, piped into shopping malls, download ed onto i-Pods, music accompan ies us from the cradle to the grave. Th anks to modern technolog y, music from all historical eras and from every part of the globe is available to many of us almost instantane ously. We listen to music and we make musicaccording to anthropol ogists, no known culture lacks this human propensity to produce, combine and organize sounds.
But why is music so important to us and how does it exert its wide-rang ing eff ects? Th ese are questions that for centuries have fascinated and occupied philosoph ers, physicists, psycholog ists, historians and, of course, composers . In the last two decades, neuroscien tists have joined the ranks of those probing and theorizing music's functions and modes of action. With the introducti on of new tools for studying neurophys iology, it is now possible to investigate what happens in the brain when we listen to or make music. Some of these research eff orts -as shown by the contributions to this issue of the Gazettedemonstra te that music is a biologicall y deeply ingrained function of the human brain and that music is basic to cognitive structure. Th is research is also providing a scientifi c basis for the use of music as a therapeuti c tool in medicine and rehabilitation. Not only is music processing dispersed throughou t the entire brain, but the brain can respond in highly plastic ways to musical input and production , and the continued and intense practice of music can lead to signifi cant structural and functional adaptation s in the brain.
Th e 18th-centu ry German writer and philosoph er Novalis wrote that 'every illness is a musical problem -its cure a musical solution.' Th is may sound like Romantic overstatem ent and yet, both biologicall y and therapeuti cally, there is perhaps more truth in these words than even their author recognized . Putting 'Music & Medicine' together provoked much lively discussion between the editors, and we are deeply sorry that Steven Karger was not here to share with us his refl ections and views as this number evolved from the planning stage into the issue you now hold in your hands.
A 
